120 related articles for article (PubMed ID: 15799868)
1. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
Oltenfreiter R; Staelens L; Hillaert U; Heremans A; Noël A; Frankenne F; Slegers G
Appl Radiat Isot; 2005 Jun; 62(6):903-13. PubMed ID: 15799868
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.
Kopka K; Breyholz HJ; Wagner S; Law MP; Riemann B; Schröer S; Trub M; Guilbert B; Levkau B; Schober O; Schäfers M
Nucl Med Biol; 2004 Feb; 31(2):257-67. PubMed ID: 15013492
[TBL] [Abstract][Full Text] [Related]
3. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents.
Oltenfreiter R; Staelens L; Lejeune A; Dumont F; Frankenne F; Foidart JM; Slegers G
Nucl Med Biol; 2004 May; 31(4):459-68. PubMed ID: 15093816
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
[TBL] [Abstract][Full Text] [Related]
5. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
[TBL] [Abstract][Full Text] [Related]
8. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.
Wagner S; Breyholz HJ; Höltke C; Faust A; Schober O; Schäfers M; Kopka K
Appl Radiat Isot; 2009 Apr; 67(4):606-10. PubMed ID: 19167232
[TBL] [Abstract][Full Text] [Related]
9. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
[TBL] [Abstract][Full Text] [Related]
10. Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.
Masuda T; Nakayama Y
J Med Chem; 2003 Jul; 46(16):3497-501. PubMed ID: 12877587
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases.
Faust A; Waschkau B; Waldeck J; Höltke C; Breyholz HJ; Wagner S; Kopka K; Schober O; Heindel W; Schäfers M; Bremer C
Bioconjug Chem; 2009 May; 20(5):904-12. PubMed ID: 19374404
[TBL] [Abstract][Full Text] [Related]
12. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
[TBL] [Abstract][Full Text] [Related]
13. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.
Rossello A; Nuti E; Catalani MP; Carelli P; Orlandini E; Rapposelli S; Tuccinardi T; Atkinson SJ; Murphy G; Balsamo A
Bioorg Med Chem Lett; 2005 May; 15(9):2311-4. PubMed ID: 15837315
[TBL] [Abstract][Full Text] [Related]
14. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
15. Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents.
Oltenfreiter R; Staelens L; Labied S; Kersemans V; Frankenne F; Noël A; Van de Wiele C; Slegers G
Cancer Biother Radiopharm; 2005 Dec; 20(6):639-47. PubMed ID: 16398616
[TBL] [Abstract][Full Text] [Related]
16. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption.
Rubino MT; Agamennone M; Campestre C; Campiglia P; Cremasco V; Faccio R; Laghezza A; Loiodice F; Maggi D; Panza E; Rossello A; Tortorella P
ChemMedChem; 2011 Jul; 6(7):1258-68. PubMed ID: 21714093
[TBL] [Abstract][Full Text] [Related]
17. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
Breuer E; Salomon CJ; Katz Y; Chen W; Lu S; Röschenthaler GV; Hadar R; Reich R
J Med Chem; 2004 May; 47(11):2826-32. PubMed ID: 15139760
[TBL] [Abstract][Full Text] [Related]
18. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
Rossello A; Nuti E; Orlandini E; Carelli P; Rapposelli S; Macchia M; Minutolo F; Carbonaro L; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
Bioorg Med Chem; 2004 May; 12(9):2441-50. PubMed ID: 15080939
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
20. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]